Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

JHEP reports : innovation in hepatology·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026
Same author

Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases.

Clinics in liver disease·2026
Same author

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease.

European radiology·2026

関連する実験動画

Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

LCAT機能の低下は,動脈硬化症の増加と関連しています.

G Kees Hovingh1, Barbara A Hutten, Adriaan G Holleboom

  • 1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Circulation
|August 3, 2005
PubMed
まとめ
この要約は機械生成です。

LCAT遺伝子の欠陥を有する個人は,HDLコレステロールが低く,トリグリセリドが高く,心血管疾患のリスクが高まります. LCATをターゲットにすることは,CVDの予防のための新しい戦略を提供することができます.

さらに関連する動画

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

関連する実験動画

Last Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

科学分野:

  • バイオケミストリー バイオケミストリー
  • 遺伝学 遺伝学とは
  • 心血管医学 心血管医学

背景:

  • 低HDLコレステロールは,心血管疾患 (CVD) の既知の危険因子です.
  • レシチン:コレステロールアシルトランスフェラーゼ (LCAT) 遺伝子変異によるHDLコレステロールの重度の低下がCVDリスクにおける役割は不明である.
  • LCAT変異のキャリアにおけるCVDリスクの理解は,LCATを治療目標として明らかにする可能性があります.

研究 の 目的:

  • LCAT遺伝子変異と心血管疾患のリスク因子の関連性を調査する.
  • LCAT遺伝子欠陥を有する個体における心血管リスクマーカーを評価する.

主な方法:

  • 評価された脂質,リポプロテイン,C反応性タンパク質 (CRP),および頸動脈のインティマ・メディア厚さ (IMT).
  • LCAT遺伝子変異の47のヘテロジゴトと58の家族対照群を比較した.
  • 年齢,性別,アルコール使用量に調整した統計分析.

主要な成果:

  • ヘテロジゴットは,HDLコレステロールの36%低下,トリグリセリドの23%増加,CRPの2.1倍増加を示しました.
  • コントロールと比較して,ヘテロジゴトの体内 Carotid IMT が有意に増加した (P<0.0015 調整後).

結論:

  • LCAT遺伝子の欠陥は,低いHDLコレステロール,高いトリグリセリド,および増加したCRPに関連しています.
  • 観察されたIMTの増加は,LCATが動脈硬化から保護することを示唆しています.
  • HDLコレステロールを高めるためにLCATをターゲットにすることが,CVDのリスクを減らすための実行可能な戦略である可能性があります.